Sugi Predict

Sugi Predict / Targets / PRDM7

PRDM7

Histone-lysine N-methyltransferase PRDM7 · Q9NQW5 · PRDM7 on Sugi Atlas →

4 patent compounds predicted against PRDM7, 2 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30797918 SCHEMBL30797918 1.00 1/20
SCHEMBL21186191 SCHEMBL21186191 0.40 1/20

Clinical trials — most relevant to PRDM7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16 nanCOMPLETED
Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI) nanRECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders nanENROLLING_BY_INVITATION
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage nanUNKNOWN
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment nanCOMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks nanRECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PRDM7 binder may also engage these)

ProteinNameSimilarity
P23497 — 0.987 P23497 →
Q9NWN3 — 0.987 Q9NWN3 →
B1H224 — 0.986 B1H224 →
Q5VYS8 — 0.986 Q5VYS8 →
Q8BVK9 — 0.986 Q8BVK9 →
Q0VET5 — 0.986 Q0VET5 →
Q8BW88 — 0.986 Q8BW88 →
Q4R739 — 0.985 Q4R739 →
Q8BG34 — 0.985 Q8BG34 →
Q921C6 — 0.985 Q921C6 →
Q6DIL6 — 0.984 Q6DIL6 →
Q8BL06 — 0.984 Q8BL06 →
Q80VH0 — 0.984 Q80VH0 →
Q5BLK4 — 0.984 Q5BLK4 →
Q7Z7J5 — 0.983 Q7Z7J5 →
Q2KIN0 — 0.983 Q2KIN0 →
Q66H04 — 0.983 Q66H04 →
Q9WUL6 — 0.983 Q9WUL6 →
Q7YRZ8 — 0.983 Q7YRZ8 →
Q9D494 — 0.983 Q9D494 →
Q7L190 — 0.983 Q7L190 →
Q8C0X8 — 0.983 Q8C0X8 →
Q3U3V8 — 0.983 Q3U3V8 →
Q6P1D7 — 0.983 Q6P1D7 →
Q3UIZ8 — 0.983 Q3UIZ8 →
O35892 — 0.982 O35892 →
Q9JIC3 — 0.982 Q9JIC3 →
Q8BLR5 — 0.982 Q8BLR5 →
P56716 — 0.982 P56716 →
Q5T0L3 — 0.982 Q5T0L3 →